

1 **Rates of Positive M-CHAT-R Screenings by Pandemic Birth and Prenatal SARS-CoV-2**
2 **Exposure**

3 ***Morgan R. Firestein**, Ph.D.¹, ***Angela Gigliotti Manassis**, M.S.², **Jen Warmingham**, Ph.D.³,
4 **Yunzhe Hu**, B.A.¹, **Morgan A. Finkel**, M.D., M.S.^{3,4}, **Margaret Kyle**, B.A.³, **Maha Hussain**,
5 M.S.³, **Imaal Ahmed**, B.A.³, **Andréane Lavallée**, Ph.D.³, **Ana Solis**³, **Vitoria Chaves**, M.S.³,
6 **Cynthia Rodriguez**, B.A.³, **Sylvie Goldman**, Ph.D.^{4,5}, **Rebecca A. Muhle**, M.D., Ph.D.^{1,4,5},
7 **Seonjoo Lee**, Ph.D.^{1,5,6}, **Judy Austin**, Ph.D.⁷, **Wendy G. Silver**, M.D., M.A.^{4,8}, **Kally C.**
8 **O'Reilly**, Ph.D.^{1,5}, **Jennifer M. Bain**, M.D., Ph.D.^{4,8}, **Anna A. Penn**, M.D., Ph.D.^{3,4}, **Jeremy**
9 **Veenstra-VanderWeele**, M.D.,^{1,3,4,5}, **Melissa S. Stockwell**, M.D., M.P.H.^{3,4,7}, **William P. Fifer**,
10 Ph.D.^{1,3}, **Rachel Marsh**, Ph.D.^{1,8}, **Catherine Monk**, Ph.D.^{1,5,9}, **Lauren C. Shuffrey**, Ph.D.¹⁰,
11 **Dani Dumitriu**, M.D., Ph.D.^{1,3,4}

12 *Dr. Firestein and Ms. Gigliotti Manassis contributed equally to this article

13 ¹Department of Psychiatry, Columbia University Irving Medical Center, New York, NY 10032

14 ²Teachers College, Columbia University, New York, NY 10027

15 ³Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032

16 ⁴New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY 10032

17 ⁵New York State Psychiatric Institute, New York, NY 10032

18 ⁶Department of Biostatistics, Mailman School of Public Health, Columbia University Irving
19 Medical Center, New York, NY 10032

20 ⁷Heilbrunn Department of Population and Family Health, Columbia University Irving Medical
21 Center, New York, NY 10032

22 ⁸Department of Neurology, Division of Child Neurology, Columbia University Irving Medical
23 Center, New York, NY 10032

24 ⁹Department of Obstetrics and Gynecology, Columbia University Irving Medical Center New
25 York, NY 10032

26 ¹⁰Department of Psychiatry, New York University Grossman School of Medicine, New York,
27 NY 10016

28

29 **Corresponding Author:**

30 Dani Dumitriu, M.D., Ph.D.

31 New York State Psychiatric Institute

32 Columbia University Irving Medical Center

33 1051 Riverside Drive, Suite 4807

34 New York, NY 10032

35 dani.dumitriu@columbia.edu

36

37

38

39

40 **Abstract**

41 Maternal stress and viral illness during pregnancy are associated with neurodevelopmental
42 conditions in offspring. Children born during the COVID-19 pandemic, including those exposed
43 prenatally to maternal SARS-CoV-2 infections, are reaching the developmental age for the
44 assessment of risk for neurodevelopmental conditions. We examined associations between birth
45 during the COVID-19 pandemic, prenatal exposure to maternal SARS-CoV-2 infection, and
46 rates of positive screenings on the Modified Checklist for Autism in Toddlers-Revised (M-
47 CHAT-R). Data were drawn from the COVID-19 Mother Baby Outcomes (COMBO) Initiative.
48 Participants completed the M-CHAT-R as part of routine clinical care (COMBO-EHR cohort) or
49 for research purposes (COMBO-RSCH cohort). Maternal SARS-CoV-2 status during pregnancy
50 was determined through electronic health records. The COMBO-EHR cohort includes n=1664
51 children (n=442 historical cohort, n=1222 pandemic cohort; n=997 SARS-CoV-2 unexposed
52 prenatally, n=130 SARS-CoV-2 exposed prenatally) who were born at affiliated hospitals
53 between 2018-2023 and who had a valid M-CHAT-R score in their health record. The COMBO-
54 RSCH cohort consists of n=359 children (n=268 SARS-CoV-2 unexposed prenatally, n=91
55 SARS-CoV-2 exposed prenatally) born at the same hospitals who enrolled into a prospective
56 cohort study that included administration of the M-CHAT-R at 18-months. Birth during the
57 pandemic was not associated with greater likelihood of a positive M-CHAT-R screen in the
58 COMBO-EHR cohort. Maternal SARS-CoV-2 was associated with lower likelihood of a positive
59 M-CHAT-R screening in adjusted models in the COMBO-EHR cohort (OR=0.40, 95% CI=0.22
60 - 0.68, $p=0.001$), while analyses in the COMBO-RSCH cohort yielded similar but non-
61 significant results (OR=0.67, 95% CI=0.31-1.37, $p=0.29$). These results suggest that children
62 born during the first 18 months of the COVID-19 pandemic and those exposed prenatally to a
63 maternal SARS-CoV-2 infection are not at greater risk for screening positive on the M-CHAT-R.

64

65

66

67

68 **Introduction**

69 Since the onset of the COVID-19 pandemic, we have gained substantial knowledge about
70 the SARS-CoV-2 virus and resulting COVID-19 pathophysiology. However, longitudinal
71 research is needed to determine long-term consequences of early exposure to both the virus and
72 the pandemic environment, especially those affecting the youngest generations.¹⁻³ Most reports
73 have provided reassuring results suggesting no association between prenatal exposure to
74 maternal SARS-CoV-2 infection and child neurodevelopment.⁴⁻⁸ One research group found that
75 a higher proportion of prenatally exposed male infants received ICD-10 codes for speech
76 disorders at age 12 months, but not at 18 months. This finding, coupled with a lower-than-
77 expected rate of SARS-CoV-2 infections, suggests a high rate of misclassification and false
78 negatives which may limit the interpretability of these results.^{9,10} Further, studies of infants born
79 during previous pandemics have shown that neurodevelopmental needs are frequently
80 unobserved until years later,¹¹ necessitating additional follow-up.

81 Beyond prenatal exposure to SARS-CoV-2, the COVID-19 generation—the generation
82 born during this pandemic—experienced an unusual environment during infancy and early
83 childhood secondary to societal changes and restrictions. Several reports from diverse
84 populations revealed neurodevelopmental differences between pandemic-born compared to pre-
85 pandemic-born children.^{4,6,7,12}

86 The COVID-19 pandemic therefore presents a two-pronged mechanism through which
87 the COVID-19 generation may be at greater risk for neurodevelopmental conditions such as
88 autism spectrum disorders.^{6,13} Maternal prenatal psychological distress has been implicated in
89 increased neurodevelopmental risk through a fetal programming framework.^{14,15} Separately,
90 maternal immune activation (MIA) is among the potential mechanisms through which prenatal

91 exposure to SARS-CoV-2 has been hypothesized to impact offspring neurodevelopment.
92 Previous outbreaks of human coronaviruses (such as SARS and Middle East Respiratory
93 Syndrome) indicate that severe infection during pregnancy may negatively affect both maternal
94 health and infant well-being, possibly through MIA.^{13,16} Based on these premises, we
95 hypothesized that infants exposed to a maternal SARS-CoV-2 in utero would be at increased risk
96 of screening positive on the M-CHAT-R.

97 Given the benefits of early intervention,^{17,18} special attention should be directed towards
98 evaluating the relationship between fetal exposure to maternal SARS-CoV-2 infection, the
99 COVID-19 pandemic environment, and child neurodevelopment. Children who were *in utero*
100 during peak periods of the pandemic are reaching the age at which early indicators of risk for
101 autism may emerge. We compared scores on the parent-report Modified Checklist for Autism in
102 Toddlers-Revised (M-CHAT-R) screener between children born before and during the pandemic
103 and those with and without prenatal SARS-CoV-2 exposure. Data were collected as part of the
104 COVID-19 Mother Baby Outcomes (COMBO) Initiative and include clinical M-CHAT-R scores
105 recorded in electronic health records (EHR) and M-CHAT-R scores obtained for research
106 purposes from children born at a large university-based medical center in New York City
107 between January 2018 and September 2021.

108

109 **Methods**

110 *Study Design and Participants*

111 Data were drawn from the COVID-19 Mother Baby Outcomes (COMBO) Initiative,
112 which includes children born at Columbia University Irving Medical Center (CUIMC)-affiliated
113 NewYork-Presbyterian (NYP) Morgan Stanley Children's Hospital and NYP Allen Pavilion

114 Hospital in New York City between January 2018 and September 2021. COMBO includes an
115 electronic health record (EHR) arm (COMBO-EHR cohort) with a waiver of consent and a
116 prospective research arm (COMBO-RSCH cohort) with on-going enrollment and consent of
117 mother-infant dyads (eFigure 1). Across the two cohorts, demographic and clinical variables,
118 including maternal SARS-CoV-2 status during pregnancy, were acquired through a combination
119 of automated abstraction and manual review of the participants' EHRs. As part of routine clinical
120 care, all CUIMC/NYP-affiliated pediatric clinics began universally administering the M-CHAT-
121 R between 16-30 months of age in February 2020, and scores are recorded in the EHR.
122 Separately, mothers enrolled in COMBO-RSCH are asked to complete the M-CHAT-R at the 18-
123 month study follow-up for research purposes. All study procedures have been reviewed and
124 approved by the CUIMC Institutional Review Board. This study followed the Strengthening the
125 Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.

126

127 ***COMBO-EHR Cohort***

128 We identified n=1747 children born in the NYP hospital system during the study period
129 with clinical M-CHAT-R scores in the EHRs. For children with more than one M-CHAT-R
130 score, we used the most recent score obtained within the valid age range. We excluded n=80
131 children because their only M-CHAT-R score was obtained outside the range of 16-30 months.
132 We excluded an additional n=3 children who received a total M-CHAT-R score of 17 that
133 resulted from all items being marked as "yes," suggesting invalid parental report. In total, we
134 included n=1664 children in COMBO-EHR analyses.

135

136 ***COMBO-RSCH Cohort***

137 At the time of this analysis, the COMBO Initiative had enrolled n=907 mother-infant
138 dyads who had been admitted to the labor & delivery unit and/or well-baby/NICU units of the
139 CUIMC-NYP hospital system in New York City during the study period. Overall, n=421
140 enrolled mothers completed the M-CHAT-R for research purposes as part of a REDCap survey
141 administered at the 18-month study time point. Sixty-two children were excluded from COMBO-
142 RSCH analyses because they had M-CHAT-R scores obtained for both clinical and research
143 purposes. These cases were only included in COMBO-EHR dataset to prioritize the analysis of
144 clinical screening data. In total, we included n=359 children in COMBO-RSCH analyses.

145

146 ***Timing of Birth Relative to the COVID-19 Pandemic***

147 The COMBO-EHR cohort includes n=442 infants born prior to the COVID-19 pandemic
148 (historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants
149 born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March
150 2020–September 2021. In contrast, all infants in the COMBO-RSCH cohort were born during
151 the COVID-19 pandemic. Therefore, the historical versus pandemic birth comparison could only
152 be conducted on the COMBO-EHR cohort. Of note, all infants in the COMBO-EHR cohort,
153 including those born prior to the pandemic (historical cohort), were assessed *during* the
154 pandemic as universal M-CHAT-R screening at pediatric clinics coincided with the onset of the
155 pandemic for unrelated reasons. Thus, every child in the COMBO-EHR cohort had *postnatal*
156 exposure to the pandemic environment.

157

158 ***Determination of Prenatal Maternal SARS-CoV-2 Infection***

159 Maternal SARS-CoV-2 status during pregnancy was determined through EHR
160 abstraction and review. Detailed descriptions of our methods for determining maternal SARS-
161 CoV-2 status during pregnancy have been reported previously^{4,5} and are outlined in eFigure 2.
162 Briefly, on March 22, 2020, CUIMC began universal testing of all delivering patients for SARS-
163 CoV-2 through nasopharyngeal polymerase chain reaction (PCR) and on July 20, 2020, universal
164 serology testing for SARS-CoV-2 antibodies was implemented. Infants born before November 1,
165 2020, were considered exposed during pregnancy if their mother had a positive PCR and/or
166 serological test during pregnancy or at delivery. If their mother had a negative PCR test and no
167 available serological test result, they were classified as unexposed. For infants born after
168 November 1, 2020, mothers could have had a pre-pregnancy infection that would result in a
169 positive serology test during pregnancy. Therefore, these infants were considered exposed during
170 pregnancy if their mother had a positive PCR and/or antigen test during pregnancy. If their
171 mothers did not have a recorded positive PCR or antigen test but had a positive serological test
172 and COVID-19 symptoms during the pregnancy, they were also considered exposed. Infants
173 were classified as unexposed if their mother had a positive serology test during pregnancy or at
174 the time of delivery, but had no symptoms during the pregnancy, had negative serological
175 testing, or had no serology test results and no symptoms during the pregnancy determined
176 through manual chart review. We have previously estimated that this approach has a 0.67%
177 false-negative rate (eMethods 1).

178

179 ***Modified Checklist for Autism in Toddlers (M-CHAT-R)***

180 The M-CHAT-R was developed to assess risk for autism based on parent report of their
181 child's development between 16-30 months of age and consists of twenty 'yes'/'no' items that
182 focus on a child's milestones as well as early autism symptoms that present between the normed
183 age span.¹⁹ Total scores are calculated and categorized into ranges of "low-risk" (0-2); "medium-
184 risk" (3-7); "high-risk" (8-20). To improve power, we collapsed across the medium-risk and
185 high-risk ranges to define a medium/high-risk range, which we defined as screening positive.
186 The M-CHAT-R has been validated as having high sensitivity and specificity as a measure for
187 likelihood of autism, with diagnoses confirmed through a variety of measures such as the Autism
188 Diagnostic Observation Schedule and is widely adopted by clinicians.^{20,21} The M-CHAT-R was
189 administered in either English or Spanish depending on the caregiver's preference.

190

191 *Statistical analysis*

192 Statistical analyses were conducted in R version 4.3.1 (R Foundation for Statistical
193 Computing).²² M-CHAT-R scores were obtained through EHR review for the COMBO-EHR
194 cohort and using a forced-choice online survey for the COMBO-RSCH cohort, resulting in no
195 missingness of data. Since participants in both cohorts were born in the same hospital system, all
196 demographic variables and other covariates were obtained via the EHRs. For each of our three
197 primary analyses, we performed separate unadjusted Chi-squared tests and multivariable logistic
198 regression models. Using data from the COMBO-EHR cohort, we performed an unadjusted Chi-
199 squared test and an adjusted logistic regression model to assess the association between birth
200 during the COVID-19 pandemic and a positive screening on the M-CHAT-R. For the subset of
201 COMBO-EHR children born during the COVID-19 pandemic and the COMBO-RSCH cohort,
202 we performed an unadjusted Chi-squared test and a multivariable logistic regression model to

203 determine the association between prenatal maternal SARS-CoV-2 status and positive screening
204 on the M-CHAT-R. All multivariable models included as covariates the child's age at
205 assessment, sex assigned at birth, maternal race and ethnicity, mode of delivery, gestational age
206 at delivery, maternal age at delivery, and insurance type as a proxy for socioeconomic status
207 (Medicaid versus commercial). To examine potential demographic differences between groups,
208 comparisons were performed using Chi-squared tests for binomial variables and Wilcoxon rank
209 sum tests for continuous variables. For the primary analyses, we report Chi-squared results for
210 univariate models and odds ratios (ORs) with 95% confidence intervals (CIs) for multivariable
211 models. For all analyses, we conducted separate subgroup analyses of full-term and preterm
212 children, as well as subgroup analyses of male and female children. For analyses of SARS-CoV-
213 2 exposure within both COMBO-EHR and COMBO-RSCH cohorts, we conducted an additional
214 sensitivity analysis omitting cases without serology testing in the EHR. Finally, we compared the
215 proportion of children screening positive on the M-CHAT-R and the age at assessment across the
216 COMBO-RSCH and COMBO-EHR cohorts using independent samples t-tests and Chi-squared
217 tests. All sensitivity analyses used multivariable models. Significance was set at $p < 0.05$.

218

219 **Results**

220 *Cohort Characteristics*

221 The COMBO-EHR cohort included $n = 1664$ children, $n = 442$ born before March 2020
222 (historical cohort) and $n = 1222$ born during the COVID-19 pandemic. In the pandemic-born
223 group, 95 dyads lacked maternal PCR and serology data or had unknown infection timing,
224 resulting in $n = 997$ and $n = 130$ SARS-CoV-2 unexposed and exposed children, respectively.
225 Characteristics of the mother-child dyads included in the COMBO-EHR cohort are summarized

226 in Table 1. The mean maternal age at delivery was 30 ± 6.24 years. The pandemic cohort
227 differed significantly from the historical cohort in maternal age at delivery ($p=0.002$), self-
228 reported race ($\chi^2=597.91$, $df=6$, $p<0.001$), ethnicity ($\chi^2=596.41$, $df=3$, $p<0.001$), infant
229 gestational age ($p=0.02$), child's age at M-CHAT-R assessment ($p<0.01$), and infant sex at birth
230 ($\chi^2=6.97$, $df=1$, $p=0.008$) (Table 1). Mothers in the SARS-CoV-2 exposed cohort differed
231 significantly from the unexposed cohort in their self-reported race ($\chi^2=8.63$, $df=5$, $p=0.12$) and
232 ethnicity ($\chi^2=12.31$, $df=2$, $p=0.002$) (Table 1). Group differences were accounted for in all fully
233 adjusted models.

234 The COMBO-RSCH cohort ($n=359$) demographic characteristics are summarized in
235 Table 2. The mean maternal age at delivery was 32 ± 5.08 years. Mother-child dyads with ($n=91$)
236 and without ($n=268$) SARS-CoV-2 exposure during pregnancy were compared on the same
237 sociodemographic characteristics described above. Mothers with a history of SARS-CoV-2
238 infection during pregnancy differed significantly from unexposed mothers in their self-reported
239 ethnicity ($\chi^2=9.16$, $df=3$, $p=0.03$). Additionally, exposed children were significantly younger at
240 the time of the M-CHAT-R assessment ($p=0.03$). Group differences were accounted for in all
241 fully adjusted models.

242 Additional analyses comparing the COMBO-EHR and COMBO-RSCH cohorts are
243 described in eMethods 2.

244

245 ***Birth During the Pandemic and M-CHAT-R Positive Screening: COMBO-EHR Cohort***

246 There was no difference in the proportion of children screening positive on the M-
247 CHAT-R between the historical and pandemic cohorts ($\chi^2=0.03$, $df=1$, $p=0.87$). Specifically,

248 22% (n=100) of the children in the historical cohort and 23% (n=283) of the children in the
249 pandemic cohort screened positive (Figure 1A). The lack of an association between birth during
250 the pandemic and M-CHAT-R positivity was maintained in a fully adjusted model accounting
251 for maternal age, child age at assessment, child sex, race, ethnicity, gestational age, and
252 insurance (OR=0.75, 95% CI=0.52–1.08, p=0.12) (Table 3). Similar non-significant findings
253 were observed in adjusted subgroup analyses of preterm (n=204) and full-term subsamples
254 (n=1460) (eTable 1) and in adjusted subgroup analyses of male (n=880) and female (n=784)
255 children (eTable 2).

256

257 ***Prenatal Maternal SARS-CoV-2 Infection and M-CHAT-R Positive Screenings: COMBO-***
258 ***EHR Cohort***

259 There was a significant association between SARS-CoV-2 exposure during pregnancy
260 and less likelihood of M-CHAT-R positive screenings, which was in the opposite direction as
261 hypothesized ($\chi^2=8.28$, $df=1$, $p=0.004$). Specifically, 23% (n=239) of unexposed children and
262 12% (n=16) of exposed children screened positive on the M-CHAT-R (Figure 1B). This
263 association remained significant in a fully adjusted model (OR=0.40, 95% CI=0.22–0.68,
264 $p=0.004$) (Table 4) and persisted in sensitivity analyses excluding cases with elevated potential
265 for misclassification of SARS-CoV-2 exposure due to missing serology testing (n=427,
266 OR=0.43, 95% CI=0.22–0.81, $p=0.01$) (eTable 3). Among full-term children, a lower proportion
267 of children with SARS-CoV-2 exposure screened positive on the M-CHAT-R (n=982, adjusted
268 OR=0.45, 95% CI=0.24–0.79, $p=0.01$), whereas this association did not reach statistical
269 significance among preterm children (n=145, OR=0.16, 95% CI=0.01–0.84, $p=0.07$) (eTable 4).

270 Within both female and male subsamples, a lower proportion of children with SARS-CoV-2
271 exposure screened positive on the M-CHAT-R (females: $n=555$, adjusted OR=0.30 95%
272 CI=0.10–0.71, $p=0.01$; males: $n=572$, OR=0.48, 95% CI=0.23–0.93, $p=0.04$) (eTable 5).

273

274 *Prenatal Maternal SARS-CoV-2 Infection and M-CHAT-R Positive Screenings: COMBO-* 275 *RSCH Cohort*

276 Overall, fewer SARS-CoV-2 exposed children screened positive (13%, $n=12$) compared
277 to 17% ($n=47$) of unexposed children in the COMBO-RSCH cohort (Figure 1C). However, this
278 association was not statistically significant ($\chi^2=0.65$, $df=1$, $p=0.42$). The lack of a significant
279 association persisted in a fully adjusted model with the same covariates as those used in the
280 COMBO-EHR analysis (OR=0.67, 95% CI=0.31–1.37, $p=0.25$) (Table 4). Similar non-
281 significant associations were observed in adjusted subgroup analyses of preterm ($n=37$) and full-
282 term subsamples ($n=322$) (eTable 6) and in subgroup analyses of male ($n=199$) and female
283 ($n=160$) children (eTable 7).

284

285 **Discussion**

286 Considering the conflicting evidence on the relationship between COVID-19 and infant
287 neurodevelopment, continued long-term monitoring of the COVID-19 generation is important
288 for public health and educational policy. We evaluated the neurodevelopmental risk of children
289 born before and during the COVID-19 pandemic and those with and without prenatal SARS-
290 CoV-2 exposure using the M-CHAT-R in a demographically diverse sample in New York City.
291 We found that children born before versus during the pandemic did not have significantly

292 different M-CHAT-R positivity rates. Contrary to our hypothesis, we found that maternal SARS-
293 CoV-2 infection during pregnancy was not associated with increased risk for a positive autism
294 screen based on the M-CHAT-R.

295 Overall, our sample had higher M-CHAT-R positivity rates compared to other samples
296 (22-23% compared to 9% in a general population).²³ Participants in our analysis primarily reside
297 in an urban city, where the prevalence of autism diagnoses is higher, potentially due to increased
298 access to healthcare services or environmental exposures unique to urban areas.²⁴ Our cohort has
299 a uniquely high percentage of Hispanic participants, a population found to have higher positivity
300 rates on the M-CHAT-R.²⁵⁻²⁷ Further, validity on the Spanish version of the M-CHAT-R was
301 conducted in Spain, which is culturally different from our study sample.²⁸

302 In our sample, maternal SARS-CoV-2 exposure during pregnancy was not associated
303 with increased risk for screening positive on the M-CHAT-R. Research suggests that SARS-
304 CoV-2 may cause MIA, with moderate but temporary changes in cytokine levels in pregnant
305 women²⁹ that could be associated with infant neurodevelopmental risk.¹⁰ Our findings align with
306 other reports of no or limited associations between prenatal SARS-CoV-2 exposure and infant
307 neurodevelopment.^{4,5,7,12} Many of these studies, however, including ours, primarily include
308 participants with mild illness. Additional exploration of the relationship between severity of
309 infection and neurodevelopment is needed.

310 Of note, the percentage of children who were exposed to SARS-CoV-2 in utero had
311 positivity rates that were closer to the expected rate in a general population; whereas the
312 unexposed children had a higher-than-expected M-CHAT-R positivity rate.³⁰ It is possible that
313 unmeasured differences between the exposed and unexposed cohorts in conjunction with the
314 subjective nature of the M-CHAT-R could contribute to the unexpected direction of this

315 association. Data suggest that maternal dispositional variables relate to reporting of their child's
316 behavior.³¹ Mothers who experienced greater stress and vigilance towards the prevention of
317 SARS-CoV-2 may be less likely to become infected and more likely to monitor and report
318 concerning behaviors through the M-CHAT-R.^{32,33} Additionally, the unexpected positivity rates
319 may be due to limitations of the M-CHAT-R as a research tool. We used only one M-CHAT-R
320 score, without follow-up, for each participant. Finally, it is important to note that all children
321 were assessed during the pandemic and had some amount of postnatal exposure to the pandemic
322 environment. Therefore, our analyses are limited to *prenatal* associations and cannot evaluate
323 associations between *postnatal* experiences and M-CHAT-R positivity.

324 Our findings suggest that neither SARS-CoV-2 infection nor birth during the pandemic is
325 associated with increased risk for autism. For many, the social and economic impact of the
326 pandemic will persist in the years to come and may continue to impact the developmental
327 trajectories of the COVID-19 generation.³⁴ There may also be intergenerational consequences
328 that could worsen existing inequalities.³⁵ Furthermore, data suggest that the impact of prenatal
329 exposures may not manifest until higher cognitive functions begin to emerge and mature.³⁶ The
330 COVID-19 pandemic has resulted in increased mental health needs amongst pregnant and
331 postpartum individuals,³⁷ and higher levels of the stress hormone cortisol during pregnancy is
332 associated with lower offspring educational attainment.³⁸ At the same time, the pandemic
333 catalyzed a number of changes in the education system.³⁹ Continued monitoring of this
334 generation is important to develop targeted and appropriate policies in education and welfare.

335

336

337

338 **Acknowledgements:** The authors are grateful for the institutional support provided by the
339 Maternal-Child Research Oversight (MaCRO) Committee and the Departments of Pediatrics,
340 Psychiatry, and Obstetrics and Gynecology at Columbia University Irving Medical Center,
341 which made possible the collection of time-sensitive information at the height of the COVID-19
342 pandemic prior to the availability of external funding opportunities. The authors wish to thank
343 the entire COVID-19 Mother Baby Outcomes (COMBO) Initiative Team for their collaborative
344 and persevering contributions throughout the COVID-19 pandemic and the Columbia University
345 Irving Medical Center Clinical Data Warehouse. Finally, the authors extend particular gratitude
346 toward the families enrolled in COMBO, whose participation continues to inform our
347 understanding of this unprecedented global event. Dr. Dumitriu has pending reimbursement for
348 consulting for Medela Inc. No funding agency played any role in any of the following: design
349 and conduct of the study; collection, management, analysis, and interpretation of the data;
350 preparation, review, or approval of the manuscript; and decision to submit the manuscript for
351 publication. Dr. Dumitriu had full access to all the data in the study and takes responsibility for
352 the integrity of the data and the accuracy of the data analysis. Drs. Firestein, Warmingham,
353 Shuffrey, Dumitriu, and Ms. Manassis are responsible for the data analysis.

354

355

356

357

358

359

360 **References**

- 361 1. López-Díaz, Á., Ayesa-Arriola, R., Crespo-Facorro, B. & Ruiz-Veguilla, M. COVID-19
362 Infection During Pregnancy and Risk of Neurodevelopmental Disorders in Offspring: Time
363 for Collaborative Research. *Biol. Psychiatry* **89**, e29–e30 (2021).
- 364 2. Ahmed, W. N., Noushin, A. M., Shafjeer, A. & Ann, R. COVID-19 and Pregnancy: Time to
365 Think beyond Medications. 11.
- 366 3. Martins-Filho, P. R., Tanajura, D. M., Santos, H. P. & Santos, V. S. COVID-19 during
367 pregnancy: Potential risk for neurodevelopmental disorders in neonates? *Eur. J. Obstet.*
368 *Gynecol. Reprod. Biol.* **250**, 255–256 (2020).
- 369 4. Shuffrey, L. C. *et al.* Association of Birth During the COVID-19 Pandemic With
370 Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to
371 Maternal SARS-CoV-2 Infection. *JAMA Pediatr.* e215563 (2022)
372 doi:10.1001/jamapediatrics.2021.5563.
- 373 5. Firestein, M. R. *et al.* Assessment of Neurodevelopment in Infants With and Without
374 Exposure to Asymptomatic or Mild Maternal SARS-CoV-2 Infection During Pregnancy.
375 *JAMA Netw. Open* **6**, e237396 (2023).
- 376 6. Brum, A. C. & Vain, N. E. Impact of perinatal COVID on fetal and neonatal brain and
377 neurodevelopmental outcomes. *Semin. Fetal. Neonatal Med.* **28**, 101427 (2023).
- 378 7. Ayed, M. *et al.* Neurodevelopmental outcomes of infants born to mothers with SARS-CoV-2
379 infections during pregnancy: a national prospective study in Kuwait. *BMC Pediatr.* **22**, 319
380 (2022).
- 381 8. Pinheiro, G. S. M. A. *et al.* Effects of intrauterine exposure to SARS-CoV-2 on infants'
382 development: a rapid review and meta-analysis. *Eur. J. Pediatr.* **182**, 2041–2055 (2023).

- 383 9. Edlow, A. G., Castro, V. M., Shook, L. L., Kaimal, A. J. & Perlis, R. H.
384 Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who Tested Positive for
385 SARS-CoV-2 During Pregnancy. *JAMA Netw. Open* **5**, e2215787 (2022).
- 386 10. Edlow, A. G. *et al.* Sex-Specific Neurodevelopmental Outcomes Among Offspring of
387 Mothers With SARS-CoV-2 Infection During Pregnancy. *JAMA Netw. Open* **6**, e234415
388 (2023).
- 389 11. Almond, D. Is the 1918 Influenza Pandemic Over? Long-Term Effects of In Utero
390 Influenza Exposure in the Post-1940 U.S. Population. *J. Polit. Econ.* **114**, 672–712 (2006).
- 391 12. Hessami, K. *et al.* COVID-19 Pandemic and Infant Neurodevelopmental Impairment: A
392 Systematic Review and Meta-analysis. *JAMA Netw. Open* **5**, e2238941 (2022).
- 393 13. San Martín-González, N. *et al.* Maternal respiratory viral infections during pregnancy and
394 offspring's neurodevelopmental outcomes: A systematic review. *Neurosci. Biobehav. Rev.*
395 **149**, 105178 (2023).
- 396 14. van den Bergh, B. R. H., Dahnke, R. & Mennes, M. Prenatal stress and the developing brain:
397 Risks for neurodevelopmental disorders. *Dev. Psychopathol.* **30**, 743–762 (2018).
- 398 15. Manzari, N., Matvienko-Sikar, K., Baldoni, F., O'Keeffe, G. W. & Khashan, A. S. Prenatal
399 maternal stress and risk of neurodevelopmental disorders in the offspring: a systematic
400 review and meta-analysis. *Soc. Psychiatry Psychiatr. Epidemiol.* **54**, 1299–1309 (2019).
- 401 16. Diriba, K., Awulachew, E. & Getu, E. The effect of coronavirus infection (SARS-CoV-2,
402 MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal–
403 fetal transmission: a systematic review and meta-analysis. *Eur. J. Med. Res.* **25**, 39 (2020).
- 404 17. Fernell, E., Eriksson, M. A. & Gillberg, C. Early diagnosis of autism and impact on
405 prognosis: a narrative review. *Clin. Epidemiol.* **5**, 33–43 (2013).

- 406 18. Granpeesheh, D., Dixon, D. R., Tarbox, J., Kaplan, A. M. & Wilke, A. E. The effects of age
407 and treatment intensity on behavioral intervention outcomes for children with autism
408 spectrum disorders. *Res. Autism Spectr. Disord.* **3**, 1014–1022 (2009).
- 409 19. Robins, D. L., Barton, M. & Fein, D. Modified Checklist for Autism in Toddlers, Revised
410 with Follow-up. American Psychological Association <https://doi.org/10.1037/t67574-000>
411 (2018).
- 412 20. Aishworiya, R., Ma, V. K., Stewart, S., Hagerman, R. & Feldman, H. M. Meta-analysis of
413 the Modified Checklist for Autism in Toddlers, Revised/Follow-up for Screening. *Pediatrics*
414 **151**, e2022059393 (2023).
- 415 21. Wieckowski, A. T., Williams, L. N., Rando, J., Lyall, K. & Robins, D. L. Sensitivity and
416 Specificity of the Modified Checklist for Autism in Toddlers (Original and Revised): A
417 Systematic Review and Meta-analysis. *JAMA Pediatr.* **177**, 373–383 (2023).
- 418 22. R Core Team. R: A language and environment for statistical computing. R Foundation for
419 Statistical Computing (2021).
- 420 23. Chlebowski, C., Robins, D. L., Barton, M. L. & Fein, D. Large-Scale Use of the Modified
421 Checklist for Autism in Low-Risk Toddlers. *Pediatrics* **131**, e1121–e1127 (2013).
- 422 24. Lauritsen, M. B. *et al.* Urbanicity and Autism Spectrum Disorders. *J. Autism Dev. Disord.*
423 **44**, 394–404 (2014).
- 424 25. Kimple, K. S., Bartelt, E. A., Wysocki, K. L. & Steiner, M. J. Performance of the Modified
425 Checklist for Autism in Toddlers in Spanish-Speaking Patients. *Clin. Pediatr. (Phila.)* **53**,
426 632–638 (2014).

- 427 26. Rea, K. E., Armstrong-Brine, M., Ramirez, L. & Stancin, T. Ethnic Disparities in Autism
428 Spectrum Disorder Screening and Referral: Implications for Pediatric Practice. *J. Dev.*
429 *Behav. Pediatr. JDBP* **40**, 493–500 (2019).
- 430 27. Windham, G. C., Lyall, K., Anderson, M. & Kharrazi, M. Autism Spectrum Disorder Risk in
431 Relation to Maternal Mid-Pregnancy Serum Hormone and Protein Markers from Prenatal
432 Screening in California. *J. Autism Dev. Disord.* **46**, 478–488 (2016).
- 433 28. Magán-Maganto, M. *et al.* Spanish Cultural Validation of the Modified Checklist for Autism
434 in Toddlers, Revised. *J. Autism Dev. Disord.* **50**, 2412–2423 (2020).
- 435 29. Jain, S., Allen, I. E., Song, D. & Piao, X. Cytokine responses to SARS-COV2 infection in
436 mother-infant dyads: a systematic review and meta-analysis. *Front. Pediatr.* **11**, 1277697
437 (2023).
- 438 30. Robins, D. L. *et al.* Validation of the Modified Checklist for Autism in Toddlers, Revised
439 With Follow-up (M-CHAT-R/F). *Pediatrics* **133**, 37–45 (2014).
- 440 31. Durbin, C. E. & Wilson, S. Convergent validity of and bias in maternal reports of child
441 emotion. *Psychol. Assess.* **24**, 647–660 (2012).
- 442 32. Crowell, J. A., Keluskar, J. & Gorecki, A. Parenting behavior and the development of
443 children with autism spectrum disorder. *Compr. Psychiatry* **90**, 21–29 (2019).
- 444 33. Gray, P. H., Edwards, D. M., O’Callaghan, M. J. & Gibbons, K. Screening for autism
445 spectrum disorder in very preterm infants during early childhood. *Early Hum. Dev.* **91**, 271–
446 276 (2015).
- 447 34. Benner, A. D. & Mistry, R. S. Child Development During the COVID-19 Pandemic Through
448 a Life Course Theory Lens. *Child Dev. Perspect.* **14**, 236–243 (2020).

- 449 35. Fitzgerald, E., Hor, K. & Drake, A. J. Maternal influences on fetal brain development: The
450 role of nutrition, infection and stress, and the potential for intergenerational consequences.
451 *Early Hum. Dev.* **150**, 105190 (2020).
- 452 36. Konijnenberg, C. Methodological Issues in Assessing the Impact of Prenatal Drug Exposure.
453 *Subst. Abuse Res. Treat.* **9s2**, SART.S23544 (2015).
- 454 37. Firestein, M. R., Dumitriu, D., Marsh, R. & Monk, C. Maternal Mental Health and Infant
455 Development During the COVID-19 Pandemic. *JAMA Psychiatry* **79**, 1040–1045 (2022).
- 456 38. Aizer, A., Stroud, L. & Buka, S. Maternal Stress and Child Outcomes: Evidence from
457 Siblings. *J. Hum. Resour.* **51**, 523–555 (2016).
- 458 39. White, M. A. & McCallum, F. *Wellbeing and Resilience Education: COVID-19 and Its*
459 *Impact on Education.* (Routledge, 2021).

460

461

462

463

464 **Figure Captions**

465

466 **Figure 1. Percent of Children Screening Positive on the M-CHAT-R in the COMBO-EHR and COMBO-RSCH Datasets.**
467 **Dashed grey lines indicate previously reported rates of positivity in low-risk, US samples.**

468

Table 1. Electronic Medical Record (COMBO-EHR) Cohort Characteristics

Variable No. (%) or Median (Min, Max)	Overall Sample (N=1664)	Historical Cohort (N=442)	Pandemic Cohort (n=1222)	Historical Cohort vs. Pandemic Cohort		SARS-CoV-2 Unexposed (N=997)	SARS-CoV-2 Exposed (N=130)	SARS-CoV-2 Unexposed vs. Exposed	
				<i>p</i> [†]	Test statistic [†]			<i>p</i> [†]	Test statistic [†]
Maternal Characteristics									
Age at Delivery (years)	30 (16, 56)	31.00 (16, 56)	30.00 (17, 55)	0.002	296990	30.00 (17.00, 55.00)	28.00 (17.00, 43.00)	0.08	70947
Insurance				<.001	49.83			0.52	0.42
Commercial	419 (25.18%)	167 (37.78%)	252 (20.62%)			213 (21.36%)	24 (18.46%)		
Medicaid	1245 (74.82%)	275 (62.21%)	970 (79.38%)			784 (78.64%)	106 (81.54%)		
Race				<.001	597.91			0.12	8.63
Black or African American	266 (16%)	71 (16.06%)	195 (15.96%)			166 (16.65%)	18 (13.85%)		
Native American or Alaskan Native	8 (0.48%)	2 (0.45%)	6 (0.49%)			3 (0.30%)	1 (0.77%)		
Asian or Asian American	65 (3.9%)	30 (6.79%)	35 (2.86%)			33 (3.31%)	2 (1.54%)		
White	400 (24.04%)	156 (35.29%)	244 (19.97%)			200 (20.06%)	21 (16.15%)		
Other or Mixed Race	608 (36.54%)	30 (6.79%)	578 (47.30%)			460 (46.14%)	76 (58.46%)		
Declined	180 (10.82%)	16 (3.62%)	164 (13.42%)			135 (13.54%)	12 (9.23%)		
Unknown	137 (8.23%)	137 (31.00%)	0 (0%)			0 (0.00%)	0 (0.00%)		
Ethnicity				<.001	596.41			0.002	12.31
Hispanic or Latino/a/x or Spanish	991 (59.56%)	144 (32.58%)	847 (69.31%)			669 (67.10%)	105 (80.77%)		
Not Hispanic or Latino/a/x or Spanish	398 (23.92%)	114 (25.79%)	284 (23.24%)			247 (24.77%)	23 (17.69%)		
Declined	95 (5.71%)	4 (0.90%)	91 (7.45%)			81 (8.12%)	2 (1.54%)		
Unknown	180 (10.82%)	180 (40.72%)	0 (0%)			0 (0.00%)	0 (0.00%)		
Infant Characteristics									
Age at M-CHAT (months)	23 (16, 30)	24 (16, 30)	21 (16, 30)	<.001	383443	21.42 (16.03, 30.00)	23.36 (16.13, 28.65)	0.04	57762
Gestational Age at Birth (weeks)	39 (23.00, 41.57)	39 (23.00, 41.29)	39.14 (23.86, 41.57)	0.02	249410	39.14 (24.14, 41.57)	39.00 (24.71, 41.29)	0.35	68099
Female Sex	784 (47.12%)	184 (41.62%)	600 (49.10%)	0.01	6.97	490 (49.15%)	65 (50.00%)	0.93	0.01

[†]Comparisons performed using Chi Squared Test for categorical variables and Wilcoxon Rank-Sum test (*W*, rank total) for continuous variables. All statistical tests were two-sided.

469

470

Table 2. COMBO Research (COMBO-RSCH) Cohort Characteristics

Variable No. (%) or Median (Min, Max)	Overall Sample (N=359)	SARS-CoV-2 Unexposed (N=268)	SARS-CoV-2 Exposed (N=91)	SARS-CoV-2 Unexposed vs. Exposed	
				p^{\dagger}	Test statistic [†]
Maternal Characteristics					
Age at Delivery (years)	32 (5)	32 (5)	32 (5)	0.70	12524
Insurance				0.84	0.35
Commercial	216 (60.2%)	163 (69.8%)	55 (60.4%)		
Medicaid	143 (39.8%)	105 (39.2%)	36 (39.6%)		
Race				0.21	8.34
Black or African American	36 (10%)	30 (11.2%)	6 (6.6%)		
Native American or Alaskan Native	3 (0.8%)	2 (0.7%)	2 (2.2%)		
Native Hawaiian or Other Pacific Islander	1 (0.3%)	1 (0.4%)	0 (0%)		
Asian or Asian American	12 (3.3%)	10 (3.7%)	2 (2.2%)		
White	153 (42.6%)	120 (44.8%)	32 (35.2%)		
Other or Mixed Race	96 (26.7%)	63 (23.5%)	33 (36.3%)		
Declined or Unknown	60 (16.7%)	42 (15.7%)	17 (18.7%)		
Ethnicity				0.03	9.16
Hispanic or Latino/a/x or Spanish	151 (42.1%)	103 (38.4%)	48 (52.7%)		
Not Hispanic or Latino/a/x or Spanish	157 (43.7%)	126 (47.0%)	31 (34.1%)		
Declined or Unknown	51 (14.2%)	39 (14.6%)	12 (13.2%)		
Infant Characteristics					
Age at M-CHAT (months)	18.44 (1.07) (16.53, 27)	18.23 (1.21) (16.53, 23.9)	18.04 (0.89) (16.53, 27)	<0.001	184167
Gestational Age at Birth (weeks)	38.77 (1.74) (30.57, 41.57)	39.14 (1.72) (30.57, 41.43)	39.00 (1.81) (30.57, 41.57)	0.90	12222

Female Sex	160 (44.6%)	115 (42.9%)	45 (49.5%)	0.34	0.93
------------	-------------	-------------	------------	------	------

471

472

Table 3. Comparison of Rates of Positive M-CHAT Screenings Between the Historical (n=442) and Pandemic (n=1222) Cohorts (COMBO-EHR)

Predictor	B	SE	Odds Ratio	95% CI	P-value
Pandemic Birth (<i>Reference: Born on or after 03/01/2020</i>)	-0.29	0.19	0.75	0.52 - 1.08	0.12
Age at M-CHAT administration (months)	-0.04	0.02	0.96	0.93 - 1.00	0.05
Gestational age (weeks)	-0.10	0.03	0.90	0.86 - 0.95	<.001
Maternal age at delivery >35	-0.01	0.01	0.99	0.97 - 1.01	0.16
Infant sex assigned at birth (Male)	0.61	0.12	1.84	1.45 - 3.12	<.001
Insurance (Medicaid)	0.75	0.20	2.11	1.45 - 3.14	<.001
Maternal Race—American Indian or Alaska Native	-0.30	1.12	0.74	0.04 - 4.72	0.78
Maternal Race—Asian	0.08	0.44	1.08	0.43 - 2.45	0.86
Maternal Race—Black or African American	0.34	0.20	1.41	0.95 - 2.09	0.10
Maternal Race—Declined	0.29	0.23	1.33	0.83 - 2.10	0.22
Maternal Race—Other Combinations Not Described	0.26	0.31	1.29	0.71 - 2.35	0.41
Maternal Race—White	0.09	0.18	1.10	0.77 - 1.56	0.61
Maternal Ethnicity—Not Hispanic or Latino or Spanish Origin	-0.29	0.19	0.75	0.51 - 1.09	0.13

486

487




Table 4. Comparison of Rates of Positive M-CHAT Screenings Between SARS-CoV-2 Exposed and Unexposed Infants Across the COMBO-EHR and COMBO-RSCH Cohorts

Predictor	B	SE	Odds Ratio	95% CI	P-value
COMBO-EHR Cohort					
SARS-CoV-2 Infection in pregnancy (n=130 exposed; n=997 unexposed)	-0.91	.28	0.40	0.22 - 0.68	0.004
Age at M-CHAT administration (months)	-0.04	0.02	0.96	0.92 - 1.01	0.09
Gestational age (weeks)	-0.13	0.04	0.88	0.82 - 0.93	<.001

Maternal age at delivery	-0.01	0.01	0.99	0.96 - 1.01	0.34
Infant sex assigned at birth (Male)	0.54	0.15	1.71	1.28 - 2.30	<.001
Insurance (Medicaid)	0.56	0.25	1.75	1.09 - 2.87	0.02
Maternal Race–American Indian or Alaska Native	0.37	1.27	1.45	0.064 - 14.64	0.77
Maternal Race–Asian	-0.13	0.59	0.88	0.24 - 2.58	0.83
Maternal Race–Black or African American	0.26	0.24	1.29	0.80 - 2.08	0.29
Maternal Race–Declined	0.46	0.26	1.58	0.95 - 2.60	0.07
Maternal Race–White	-0.05	-0.06	0.95	0.61 - 1.45	0.80
Maternal Ethnicity–Declined	-0.55	0.36	0.58	0.28 - 1.14	0.12
Maternal Ethnicity–Not Hispanic or Latino or Spanish Origin	-0.39	0.24	0.68	0.42 - 1.08	0.11

COMBO-RSCH Cohort

SARS-CoV-2 Infection in pregnancy (n=91 exposed; n=268 unexposed)	-0.42	0.37	0.67	0.31 - 1.37	0.25
Age at M-CHAT administration (months)	-0.30	0.13	0.75	0.56-0.98	0.03
Gestational age (weeks)	-0.26	0.09	0.75	0.56 - 0.98	0.005
Maternal age at delivery	-0.10	0.03	0.91	0.85-0.98	0.004
Infant sex assigned at birth (Male)	0.78	0.34	2.18	1.15-4.30	0.02
Insurance (Medicaid)	0.30	0.40	1.35	6.18-2.98	0.45
Maternal Race–American Indian or Alaska Native	0.93	1.40	2.53	0.10-35.94	0.51
Maternal Race–Asian	1.11	0.82	3.03	0.54- 14.18	0.18
Maternal Race–Black or African American	0.12	0.56	1.13	0.36-3.32	0.83
Maternal Race–Declined	-0.81	0.63	0.45	0.12-1.43	0.19
Maternal Race–White	-0.12	0.44	0.89	0.37-2.09	0.79
Maternal Ethnicity–Declined	0.18	0.59	1.20	0.36-3.81	0.76
Maternal Ethnicity–Not Hispanic or Latino or Spanish Origin	-0.56	0.46	0.57	0.23-1.39	0.22



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.24.24090992>; this version posted February 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.